摘要
目的探讨胃癌临床病理特征与Kirsten大鼠肉瘤病毒癌基因同源物KRAS基因突变相关性。方法选取2016年1月至2019年12月间陕西省核工业二一五医院收治的105例胃癌患者作为胃癌组,同期选取105例健康体检者作为对照组,抽取两组受试者的血液学样本,检测KRAS基因突变情况,调查患者的临床病理特征并进行相关性分析。结果胃癌组的癌胚抗原(CEA)、糖类抗原(CA199)和CA125值均高于对照组,差异均有统计学意义(均P<0.05)。胃癌组的KRAS基因突变率为41.0%,高于对照组的1.9%,差异有统计学意义(P<0.05)。在胃癌组中,G12D突变24例,G12V突变16例,G13D突变3例;对照组突变2例为G12D突变。在胃癌组中,直线相关分析显示KRAS基因突变与组织学分化、神经脉管侵犯、临床分期、淋巴结转移、CEA、CA199和CA125都存在相关性,差异均有统计学意义(均P<0.05)。结论胃癌患者的KRAS基因突变比较常见,多为第12外显子上的突变,与患者的临床病理特征和常见肿瘤标志物都存在相关性。
Objective To explore the correlation between the clinicopathological characteristics of gastric cancer and the mutations of Kirsten rat sarcoma viral oncogene homolog(KRAS)gene.Methods From January 2016 to December 2019,105 patients with gastric cancer treated at Lueyang County People’s Hospital were selected as the gastric cancer group,and another 105 healthy participants who underwent physical examination at the hospital were selected as the control group during the same period.Blood samples were collected and the mutation of KRAS gene was detected.The correlation between clinicopathological characteristics and KRAS mutation was investigated.Results The serum carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA199)and CA125 were significantly higher in the gastric cancer group than in the control group(all P<0.05).In the gastric cancer group,the KRAS gene mutation rate were 41.0%,which were significantly higher than 1.9%of the control group(P<0.05).In the gastric cancer group,G12 D mutations occurred in 24 paitients,G12 V mutations in 16 patients,and G13 D mutations in 3 patients.G12 D mutation occurred in 2 patients in the control group.Linear correlation analysis showed that there were correlation between KRAS gene mutations and histological differentiation,neurovascular invasion,clinical staging,lymph node metastasis,CEA,CA199,and CA125 in the gastric cancer group(all P<0.05).Conclusion KRAS gene mutations are common in patients with gastric cancer,most of which are mutations in exon 12,which are related to the clinicopathological characteristics and common tumor markers.
作者
杨学超
田延龙
高晓
屈红阳
YANG Xue-chao;TIAN Yan-long;GAO Xiao;QU Hong-yang(Department of Pathology,NO.215 Hospital of Shaanxi Nuclear Industry,Xianyang 712000,China;Department of General Surgery,Lueyang County People's Hospital&Lueyang County Tianjin Hospital of Traditional Chinese Medicine,Hanzhong 724300,China)
出处
《中国肿瘤临床与康复》
2020年第5期582-585,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
